Mutual of America Capital Management LLC Sells 2,551 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mutual of America Capital Management LLC lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 79,178 shares of the medical equipment provider’s stock after selling 2,551 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Lantheus were worth $8,690,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of LNTH. Farallon Capital Management LLC boosted its position in Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock valued at $92,316,000 after acquiring an additional 1,269,900 shares during the last quarter. Swedbank AB bought a new stake in Lantheus during the first quarter valued at $26,346,000. Vanguard Group Inc. boosted its position in Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after acquiring an additional 389,828 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Lantheus during the second quarter valued at $26,794,000. Finally, 2Xideas AG bought a new stake in Lantheus during the first quarter valued at $10,642,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH opened at $76.22 on Tuesday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm has a market capitalization of $5.30 billion, a PE ratio of 12.68 and a beta of 0.51. The company’s 50-day moving average is $104.95 and its 200 day moving average is $96.65.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Friday, November 8th. JMP Securities dropped their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. B. Riley upped their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.